Login to Your Account



Takeda Takes Global Hematide Rights In $535M Affymax Deal

By Karen Pihl-Carey


Wednesday, June 28, 2006
Entering its first major global partnership, privately held Affymax Inc. turned to its Japanese partner Takeda Pharmaceutical Co. Inc. to grant the rest-of-the-world rights to its anemia drug, Hematide. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription